The ability of TRAIL to selectively induce the extrinsic apoptotic pathway in cancer cells via its trimeric binding to cell surface death receptors TRAIL-R1 (DR4) and TRAIL-R2 (DR5) provided the basis for developing TRAIL receptor agonists as a therapeutic approach [1, 2]. This evidence concerns the gene TNFRSF10A and cancer.